Exopharm Limited announced further management changes. With most of the planned outcomes fully achieved and reduced day-to-day executive demands, Dr. Ian Dixon, Founding Chief Executive Officer, employment as CEO is expected to end in early calendar year 2024. Dr. Dixon and the Company have determined to make the following changes: The Company has given Dr. Dixon the required 6-months' notice of termination of his role as Chief Executive Officer; Dr. Dixon will continue as CEO until the end of his notice period, or such other earlier date as may be mutually agreed; Dr. Dixon remains a Director of the company.